• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Shore on study of patient preference between darolutamide and enzalutamide in mCRPC

Video

Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial presented at the 2021 ASCO Annual Meeting. The study is a prospective, randomized, open-label, multicenter, crossover, trial that assessed patient preference between darolutamide (Nubeqa) and enzalutamide (Xtandi) in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer. Shore is medical director of the Carolina Urologic Research Center.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.